Research & Education

Master Protocols - A New Paradigm for Advancing Therapeutic Options: Lung-MAP (S1400), ALCHEMIST and NCI MATCH

Thursday, October 1, 2015 at 9 p.m. EDT - Recording Available
David R. Gandara, MD

David R. Gandara, MD
Professor of Medicine
Director, Thoracic Oncology
UC Davis Comprehensive Cancer Center

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

    Deb Whippen-Nothing to Disclose

Name of Activity: 

 

A New Paradigm for Advancing Therapeutic Options: Lung-MAP (S1400), ALCHEMIST and NCI MATCH

Date of Activity:

 

10/01/2015

Faculty/Speaker(s):

Financial DISCLOSURES

 

David R. Gandara, MD-Speaker

Research Grant from: Astrazeneca, Bristol-Meyer Squibb, Clovis, Genentech, JNJ, Lilly, Merck and Novartis.

Cosultant: Astrazeneca, Bristol-Meyer Squibb, Boehringer-Ingelheim, Celgene, Clovis, Genentech, Guardant, Lilly, Merk, Novartis, Pfizer, Synta.

Ramaswamy Govindan, MD /Moderator – Pfizer: Advisory Board, Celgene: Advisory Board, AztraZeneca: Advisory Board, INC Research: Consulting, AbbVie: Consulting, Advisory Board and Honorarium, MSK: Advisory Board.

 

 

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

       Yes     

If yes, please list: Supported by an unrestricted grant from Celgene, Bristol-Meyer Squibb and Genentech

IASLC continues the Lung Cancer  with this LIVE WEBINAR featuring Dr. David R. Gandara.

In this program Dr. Gandara will discuss the following:

In recent years, our understanding of non-small cell lung cancer (NSCLC) has evolved from thinking of this malignancy as a single disease, or a small number of histologic subtypes, to now a multitude of genomically-defined subsets, both in adenocarcinoma and squamous lung cancer. In the development of new targeted therapies against these abnormalities, so-called Master Protocols offer a number of advantages over traditional single study designs for drug-biomarker approval, including a common infrastructure, homogeneous patient populations with consistent eligibility across multiple independent sub-studies, and the ability to screen large numbers of patients in rapid fashion. These Master Protocols can be so-called "Umbrella" design (multiple genomically-driven sub-studies in one cancer type, such as Lung-MAP or ALCHEMIST, or "Basket" design (multiple genomically-driven sub-studies in multiple cancer types). This presentation will discuss this new paradigm, with emphasis on the Lung-MAP trial in lung cancer.

After attending this session, participants will be able to:

  • Demontrate the rationale for the new clinical trial paradigm employing Master Protocol designs
  • Illustrate the Lung-MAP trial in lung cancer
  • Recognize amendments and modifications to the Lung-MAP trial that have been implemented recently

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

 

CME INFORMATION:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

In recent years, our understanding of non-small cell lung cancer (NSCLC) has evolved from thinking of this malignancy as a single disease, or a small number of histologic subtypes, to now a multitude of genomically-defined subsets, both in adenocarcinoma and squamous lung cancer. In the development of new targeted therapies against these abnormalities, so-called Master Protocols offer a number of advantages over traditional single study designs for drug-biomarker approval, including a common infrastructure, homogeneous patient populations with consistent eligibility across multiple independent sub-studies, and the ability to screen large numbers of patients in rapid fashion. These Master Protocols can be so-called "Umbrella" design (multiple genomically-driven sub-studies in one cancer type, such as Lung-MAP or ALCHEMIST, or "Basket" design (multiple genomically-driven sub-studies in multiple cancer types). This presentation will discuss this new paradigm, with emphasis on the Lung-MAP trial in lung cancer.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

DOWNLOAD RECORDING

IASLC Financial/Commercial Relantionships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

IASLC Lung Cancer Grand Rounds webinars will continue throughout 2015. This program is overseen and planned by the IASLC Education Committee. Education Committee members who are responsible for oversight of Live Internet Courses such as this Webinar are Matthew Steliga, MD, and Sumatra Mandrekar, MD. The goal is to hold one program monthly. Participants are informed regarding any conflict of interest when registering for the program and once registered, complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME credit is only available to attendees of the live webinar. 

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Thursday, October 1, 2015 at 9:00:00 PM EDT UTC-4 hours
Denver (U.S.A. - Colorado) Thursday, October 1, 2015 at 7:00:00 PM MDT UTC-6 hours
London (United Kingdom - England) Friday, October 1, 2015 at 2:00:00 AM BST UTC+1 hour
Rome (Italy) Friday, October 1, 2015 at 3:00:00 AM CEST UTC+2 hours
New Delhi (India - Delhi) Friday, October 1, 2015 at 6:30:00 AM IST UTC+5:30 hours
Moscow (Russia) Friday, October 1, 2015 at 4:00:00 AM MSK UTC+3 hours
Shanghai (China - Shanghai Municipality) Friday, October 1, 2015 at 9:00:00 AM CST UTC+8 hours
Sydney (Australia - New South Wales) Friday, October 1, 2015 at 11:00:00 AM AEST UTC+10 hours
Tokyo (Japan) Friday, October 1, 2015 at 10:00:00 AM JST UTC+9 hours
Corresponding UTC (GMT) Friday, October 1, 2015 at 1:00:00 AM     

How to use the Time Zone Converter